Publication Name	World Journal of Methodology
Manuscript ID	60504
Country	Italy

Received	2020-11-01 13:01
Peer-Review Started	2020-11-01 13:02
To Make the First Decision
Return for Revision	2020-11-30 01:46
Revised	2020-12-02 10:09
Second Decision	2021-03-23 07:13
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2021-03-29 03:46
Articles in Press	2021-03-29 03:46
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2021-04-29 07:39
Publish the Manuscript Online	2021-05-12 13:46

ISSN	2222-0682 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Infectious Diseases
Manuscript Type	Systematic Reviews
Article Title	Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Fausto Petrelli, Sara Cherri, Michele Ghidini, Gianluca Perego, Antonio Ghidini and Alberto Zaniboni
Funding Agency and Grant Number
Corresponding Author	Fausto Petrelli, MD, Doctor, Medical Sciences, Asst Bergamoo Ovest, Piazzale ospedale 1, Milano 20124, Italy. faustopetrelli@gmail.com
Key Words	Tocilizumab; COVID-19; Pandemic; Treatment; Meta-analysis; Review
Core Tip	Coronavirus disease 2019 (COVID-19) infection is associated with a citokine storm during acute phase. Interleukin-6 is a key player in this systemic inflammation. We evaluated the effect of tocilizumab (TCZ) on the outcomes of COVID-19 pneumonia. Mortality was reduced in patients treated with TCZ (Odds ratio =0.64, 95% confidence intervals: 0-47-0.87; P < 0.01). We conclude that TCZ may improve outcome of COVID-19 infected patients.
Publish Date	2021-05-12 13:46
Citation	Petrelli F, Cherri S, Ghidini M, Perego G, Ghidini A, Zaniboni A. Tocilizumab as treatment for COVID-19: A systematic review and meta-analysis. World J Methodol 2021; 11(3): 95-109
URL	https://www.wjgnet.com/2222-0682/full/v11/i3/95.htm
DOI	https://dx.doi.org/10.5662/wjm.v11.i3.95

Full Article (PDF)	WJM-11-95.pdf
Full Article (Word)	WJM-11-95.docx
Manuscript File	60504_Auto_Edited_LM.docx
Answering Reviewers	60504-Answering reviewers.pdf
Audio Core Tip	60504-Audio core tip.m4a
Biostatistics Review Certificate	60504-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	60504-Conflict-of-interest statement.pdf
Copyright License Agreement	60504-Copyright license agreement.pdf
Non-Native Speakers of English Editing Certificate	60504-Language certificate.pdf
Peer-review Report	60504-Peer-review(s).pdf
Scientific Misconduct Check	60504-Bing-Wang JL-1.jpg
Scientific Misconduct Check	60504-Scientific misconduct check.pdf
Scientific Editor Work List	60504-Scientific editor work list.pdf